Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ -- Senda Biosciences, a Flagship Pioneering company creating novel categories of medicines based on Intersystems Biology, today announced the formation of its Scientific Advisory Board (SAB). Senda's SAB is composed of leading experts across immunology, microbiology, biochemistry, and neurology, and will collaborate with Senda's leadership to support and advance the new research discipline of Intersystems Biology. This discipline focuses on how molecular connections among botanical, bacterial, and human cells—coevolved over millennia—define health and disease.
"We are thrilled to have attracted some of the brightest minds in their fields to our SAB," says Guillaume Pfefer, PhD, chief executive officer of Senda. "The deep expertise of the SAB will be pivotal to the advancement of our novel approach to medicines development, rooted in an unparalleled understanding of interspecies molecular connections. This distinguished group will contribute invaluable guidance to Senda as we continue to pursue new ways to harness the power of the 'pharmacy within us' to treat some of society's most intractable diseases and help patients in need." Professor Luke O'Neill, PhD, chair of biochemistry at Trinity College Dublin and member of Senda's Board of Directors, says, "The science being pursued by Senda is unique and represents the next frontier in the understanding of human biology. Senda's Intersystems BIology platform has applications in a wide variety of therapeutic areas and holds the potential to transform the lives of patients. The members of the SAB are recognized leaders in their respective fields, and their diversity and scientific excellence will be an invaluable resource for Senda as its first programs approach the clinic."